Dr Reddys Laboratories Ltd Research Report - 22nd Feb 2017

Pharmaceutical | Published on Feb 22nd 2017


Dr. Reddy’s Laboratories (DRL) posted lower than expected results for 3QFY2017. In INR terms, the consolidated revenues came in at Rs3,707cr (v/s. Rs4,000cr expected) v/s. Rs3,989cr in 3QFY2016, down 6.6% yoy, mainly driven by pressure on the generic market. The global generic market with sales at Rs3,064cr (down 9.0% yoy), was mainly lead by Europe (Rs214.8cr, up 11% yoy) and Emerging market (Rs594.8cr, a yoy dip of 7%). The PSAI segment posted sales of Rs540cr, up 6.0% yoy. On the operating front, the EBIT margin came in at 9.7% (v/s. 17.1% expected) v/s. 18.8% in 3QFY2016. Consequently, the PAT came in at Rs470cr (v/s. Rs536cr expected) v/s. Rs579cr in 3QFY2016, a yoy de-growth of 18.8%. We maintain our Neutral rating.

Download Full Report


CMP 2,899
Target Price
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Public & Others8.0
Grand Total100.0

Trade Securely


Portfolio Tracking & Trading Application View Demo